Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Merck (MRK) is a Top Value Stock for the Long-Term

Is Merck stock a buy after the company guided to $5 billion to $5.5 billion in sales of its Covid pill this year? Is MRK stock a buy now?

Is Merck Stock A Buy As It Eyes At Least $5 Billion From Its Covid Pill?

Enbridge

Altria

Realty Income Corp

Royal Bank of Canada

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The 2022 bear market rages on, with the 3rd worst start to the year for stocks in history. Growth stocks are getting wrecked but low volatility, high-yield blue-chips offer a shelter in the storm.

9 High-Yield Blue-Chips To Help You Sleep Well At Night In This Bear Market

AbbVie

Amgen

Baxter

Quest Diagnostics

Humana

Zoetis

As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.

7 Defensive Dividend Healthcare Stocks to Buy Now

Apple

Boeing

Salesforce

Cisco Systems

Chevron

Home Depot

Honeywell

Intel

Coca-Cola

Microsoft

NIKE

Visa

It sure gets your attention when the Dow Jones Industrial Average drops 1,000 points. But it helps, too, to know why.

Here Are The 10 Stocks That Pummeled The Dow The Most

With a boost from an earnings beat and big sales of its Covid pill, Merck nears a breakout and makes the list of new buys by top funds. The post Breakout Watch: Large-Cap Leader Merck In Spotlight After Earnings Beat And Big Covid Pill Sales appeared first on Investor's Business Daily.

Breakout Watch: Large-Cap Leader Merck In Spotlight After Earnings Beat And Big Covid Pill Sales

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The conversation will take place Wednesday, May 11, at 11:40 a.m. ET. Investors, analysts, members of the media and the general public are invited to listen at https://bofa.veracast.com/webcasts/bo

Merck to Participate in Bank of America Securities 2022 Healthcare Conference

Biogen

Bristol-Myers

Eli Lilly

Pfizer

Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.

Called to Account: Drug companies are making an accounting change after the SEC cracked down on Biogen

ASML Hld

Comcast

CVS Health

Micron Technology

NextEra Energy

Investors are fearful of risky investments, choosing to buy proven, safe stocks to hold for the long term. The post 7 Safe Stocks to Buy in May 2022 appeared first on InvestorPlace.

7 Safe Stocks to Buy in May 2022

BioNTech SE

Gilead Sciences

Check out these pharmaceutical stocks in the stock market today.

Top Pharmaceutical Stocks To Watch In May 2022

Merck's Keytruda-chemotherapy combo could soon be approved to treat cervical cancer in the European Union.

What This Regulatory News Could Mean for Merck

Bank of America

DTE Energy

NRG Energy

PepsiCo

Phillips 66

When every rally attempt fails, the big risk-on day Thursday aside, market veterans know that it is likely that the path of least resistance for the stock market is lower.

7 Goldman Sachs Conviction List Dividend Stocks That Can Weather a Huge Sell-Off

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With MSI-H or dMMR Tumors in Five Different Types of Cancer

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves KEYTRUDA Plus Chemo for Patients With Persistent, Recurrent or Metastatic Cervical Cancer PD-L1 (CPS ≥1)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

The company delivered resounding beats on both the top and bottom lines in its first quarter and raised guidance.

Why Merck Crushed the Market Today

Merck CFO Caroline Litchfield discussed the state of M&A in the biotech sector, the Covid-19 pandemic, and the future of Keytruda.

The Pandemic's Impact on Merck Is Lessening, CFO Says

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.

Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.

Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B

Merck & Co., Inc. (NYSE:MRK ) Q1 2022 Results Conference Call April 28, 2022 8:00 AM ET Company Participants Peter Dannenbaum - VP, IR Rob Davis - President and CEO Caroline Litchfield - CFO Dr. Dean Li - President, Merck Research Labs Conference Call Participants Ed Carter - Barclays Mohit Bansal - Wells Fargo Seamus Fernandez - Guggenheim Chris Schott - JP Morgan Chris Shibutani - Goldman Sachs Umer Raffat - Evercore ISI Daina Graybosch - SVB Leerink Andrew Baum - Citi Louise Chen - Cantor Mara Goldstein - Mizuho Colin Bristow - UBS Operator Good morning. My name is Grace Lachrin.

Merck & Co., Inc. (MRK) CEO Rob Davis on Q1 2022 Results - Earnings Call Transcript

Merck's mega-blockbuster Keytruda was given the nod to treat patients with a type of endometrial cancer in the U.S.

Could This FDA Approval Be a Boost for Merck?

The stronger-than-expected earnings reflect both the blockbuster sales of Merck's new Covid-19 antiviral pill, but also a steady recovery from the Covid-19 pandemic.

Merck Beats Earnings Estimates. The Stock Is Up.

Merck & Co Inc's (NYSE: MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%.

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

Merck & Co. Inc. shares rose 1.9% in premarket trade Thursday, after the drug company topped estimates for the first quarter, buoyed by more than $3 billion in sales of its COVID-19 antiviral. The company posted net income of $4.310 billion, or $1.70 a share, for the quarter, up from $2.745 billion, or $1.08 a share, in the year-earlier period.

Merck shares pop premarket after earnings beat as COVID antiviral sales top $3 billion

Merck & Co posted better-than-expected first-quarter earnings and raised its full-year sales estimate on strength from its top-selling cancer drug Keytruda, human papillomavirus (HPV) vaccine Gardasil and its COVID-19 antiviral pill molnupiravir.

News for Merck Stock (MRK)